Contact Information:

PeploBio Ltd.
The Surrey Technology Centre
40 Occam Road
Guildford | GU2 7YG

IncelIDX, Inc 30920 Huntwood Ave, Hayward, CA 94544

Release Date:

10/04/2024





FOR IMMEDIATE RELEASE

PeploBio and IncelIDX partner to launch the First Long COVID test in the UK and EU.

[Guildford, Surrey] - Developed using incellKINE Long Hauler Index technology, PeploBio and IncellDX launch the first laboratory developed test in the UK and EU to help diagnose long COVID, providing doctors with accurate insights into personalised treatment approaches.

The typical symptoms of long COVID, ranging from fatigue, brain fog, shortness of breath, insomnia, to a spectrum of cardiovascular issues, are not exclusive to any single condition. This technological breakthrough aims to provide physicians with a definitive tool to differentiate long COVID from other diseases sharing similar symptoms such as Lyme and ME-CFS.

Dr. Bruce Patterson, CEO at IncellDX, emphasised the significance of this partnership - "Our collaboration with PeploBio marks a pivotal moment in the battle against long COVID. The incellKINE Long Hauler Index technology enables us to identify a distinctive immunologic profile unique to long COVID patients, providing a crucial first step for personalised treatment strategies."

Dr. Nico Lambri, Director of Business Development and Co-Founder at PeploBio, echoed Dr. Patterson's sentiments - "Our mission at PeploBio is to drive innovation in diagnostics, and our partnership with IncellDX underscores our commitment to advancing healthcare solutions. The introduction of this test fills a critical gap, empowering healthcare professionals with the tools needed to address the challenges posed by long COVID."

About PeploBio

PeploBio is an ISO 15189 accredited clinical laboratory, committed to elevating precision medicine and bringing innovative diagnostic solutions to improve patient outcomes.

About IncellDX

IncelIDx is a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer. The company's innovative technology platform enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.

For media enquiries, please contact:

info@peplobio.co.uk customerservice@incelldx.com